@entity43 is the fifth most common @entity5 and the leading cause of mortality among the gynecologic @entity5 . @entity43 is a very devastating disease it is rarely diagnosed in its early stages, and it is usually quite advanced by the time diagnosis is made leading to very poor outcomes. It is believed that in advanced stage @entity43 cells produce a protein that enables the @entity5 cells to proliferate and become resistance to conventional drug treatments. Development of new treatment options strongly relies on understanding the @entity43 ability to proliferate and to attack the cells using combination drug treatments that are synergistic. Recent studies in our laboratory have indicated that the exposure of @entity14685 (TQ) and @entity3089 ( @entity3090 ) to @entity263 . This study was executed to investigate the effectiveness of TQ and @entity3090 on reducing early stage @entity43 cells. A total of 72 wells were plated with (105) @entity1 @entity43 cells according to standard lab protocols. Each group was subdivided into 4 groups. Group 1 served as control and groups 2, 3, and 4 were treated with TQ (16   M), @entity3090 (3   M), and TQ + @entity3090 , respectively. Biomarkers and morphological evaluations were performed following standard lab techniques. The results of the study revealed: (1) an increase in @entity842 following administration of @entity3090 and the combination at 24 and 48 hours (p<0.05) and (2) no membrane or cellular damage to the cells at all phases. The results of this study suggest used in combination have shown to be more effective method for manipulating @entity1 @entity43 cells than when used alone.

Pathophysiological Responses Associated with Exposure to TQ and @entity3090 Using XXXX Ovarian @entity5 Like Cells.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'ovarian cancer', 'Ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['Caov-3'] @entity263 :: ('MESH:D011471', 'Disease') :: ['adenocarcinoma of the prostate, colon, and pancreas'] @entity14685 :: ('MESH:C003466', 'Chemical') :: ['Thymoquinone'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer'] @entity3089 :: ('MESH:C045651', 'Chemical') :: ['Epigallocatechin-3-gallate'] @entity3090 :: ('CHEBI:4806', 'Chemical') :: ['EGCG'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']
@entity1 :: (9606,Species) :: ['CAOV-3']
